Nov 5, 2026 · about 100 roles
Not linked to AIAgios is cutting its research and development headcount by more than 100 roles over 2026, a fall of more than 35% from 2025, with about $11 million of one-time costs in the fourth quarter; chief executive Brian Goff said on the results call that it had right-sized its operating model to support a narrower focus on rare blood-disease (hematology) programmes.
The reason Agios gave
"Over the course of 2026, Agios reviewed its operating model, and will have reduced its R&D headcount by over 100 roles by year-end, representing a more than 35% decrease compared with 2025. The company expects the associated cost savings of these reductions to be realized in 2027." ... "With this commercial infrastructure, alongside a strong balance sheet and a disciplined operating model, Agios is well positioned for sustained growth as a focused, rare hematology company."Agios, in its third-quarter 2026 results release of 5 November 2026 (the second passage is chief executive Brian Goff's)
Neither the release nor the results call mentions AI, and no report read tied the cut to AI.
Source: Agios Pharmaceuticals: third-quarter 2026 results (SEC filing, exhibit 99.1). Checked Nov 8, 2026.